Navigation Links
Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
Date:10/18/2018

On June 11 of this year, two reports published in the journal Nature Medicine caused the emerging field of gene-editing therapeutics to hold its collective breath. Two different research teams independently found that CRISPR-Cas9 gene editing of non-transformed human cells occurred with a high frequency of p53 gene mutation. Mutations in the p53 gene have the distinction of being one of the most common genetic alterations in human cancers; and p53 mutations promote the formation of cancers in many different human organs and tissues.

Warnings have been sounded in both the scientific press and business press that this newly recognized problem with the highly regaled CRISPR-Cas9 technology could compromise or even preclude its envisioned future as a versatile, powerful new therapeutic. Uniformly, scientific experts have explained that the new failing is caused by the editing actions of CRISPR-Cas9 provoking p53-dependent cell death programs. As a result, only edited cells that start with or obtain p53 mutations, which disable the cell death programs, would be obtained.

This explanation, favored by most gene-editing and p53 gene experts, leaves the gene-editing field in a pickle. There is no apparent simple fix for it; and even years of future research might not yield a suitable remedy. Some experts have suggested that the new therapeutic field might have to limp forward with patients weighing the benefits of therapy against the risk of therapy-induced cancers.

Today, a brief essay, published in The CRISPR Journal, suggests a way out of this troublesome situation. James L. Sherley, M.D., Ph.D., founder and director of Asymmetrex offers a different perspective on the cause of the June 11 CRISPR-Cas9 findings. Asymmetrex was founded on research that identifies the p53 gene as a regulator of adult tissue stem cell kinetics and intellectual property that leverages this insight to identify, quantify, and expand adult tissue stem cells.

Sherley proposes that tissue stem cells are the only cells in the studied cultures that have the multiplication capacity required to produce large gene-edited cell clones. However, normal p53 causes stem cells to undergo continuous asymmetric self-renewal divisions, which keep their numbers low. So, normally after an editing event their number remains small. In contrast, if stem cells obtain a p53 mutation, their asymmetric self-renewal shifts to symmetric self-renewal, which promotes exponential expansion of large, edited clones that have p53 mutations.

Asymmetrex holds patents for using naturally occurring cellular factors to shift adult tissue stem cells, from diverse organs and tissues, from asymmetric self-renewal to symmetric self-renewal while maintaining normal p53. The action of these factors is reversible. So, in addition to providing an alternative explanation, Sherley’s response offers a simple solution. Adding the Asymmetrex factors to culture medium in gene-editing experiments is predicted to yield edited clones that retain normal p53 expression. Removal of the factors will restore edited stem cell clones back to asymmetric stem cell function for use in therapeutic applications.

Although gene editing is not a specific interest for Asymmetrex, the company is interested in developing stem cell-related tools to better enable the new therapeutic discipline. Sherley has written previously on the idea of “stemgene therapy.” Regarding his current proposal, he says, “It’s a simple test that could address a major problem for gene editing. They can try it with or without involving Asymmetrex at first, but involving us sooner would be wiser.”

Asymmetrex continues to pursue gene therapy and gene-editing companies to develop partnerships based on the company’s unique stemgene-enabling stem cell counting and stem cell expansion technologies. Because successful targeting stem cells is a crucial aspect of achieving durable gene therapies, both of these capabilities have singular potential for advancing gene and gene-editing therapeutics.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at https://www.prweb.com/releases/asymmetrex_suggests_a_stemgene_relief_from_recent_cancer_woes_about_crispr_cas9_gene_editing_therapies/prweb15848432.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
2. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
3. Recovery of Hawaiian green sea turtles still short of historic levels, Stanford-led study suggests
4. Survey of physicians suggests tablets more useful than smartphones
5. Low levels of toxic proteins linked to brain diseases, study suggests
6. Evidence suggests Antarctic crabs could be native
7. Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
8. U of T-led study cracks universal RNA code, suggests a new cause for autism
9. Study suggests way to fight therapy resistant leukemia by blocking DNA repair
10. HB-EGF protects intestines from a variety of injuries, pair of studies suggests
11. Latest research suggests moderate coffee consumption is not associated with increased CVD risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/6/2019)... (PRWEB) , ... June 05, 2019 , ... ... role as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its ... a preeminent anatomic pathology platform that provides services to more than one dozen ...
(Date:6/4/2019)... , ... June 04, 2019 , ... Harper was three ... X-rays revealed severe elbow dysplasia, which caused painful osteoarthritis in the joints. ... Her parents were heartbroken. , The surgical specialist, Dr. Christopher Eich of ...
(Date:6/3/2019)... ... 2019 , ... Stay on top of current hot topics through free webinars ... all webinars is free, so be sure to register today to save your place! ... to see our upcoming webinars: , CLINICAL TRIALS , June 10 – A ...
Breaking Biology News(10 mins):
(Date:5/15/2019)... ... May 16, 2019 , ... Emulsifiers are the ... and beverage products rely on these ingredients to create stable quality food that ... This paradigm shift triggers food formulators to seek out alternatives for starches, gums ...
(Date:5/8/2019)... ... , ... Standing at 16.2 hands, Atlas is on the large side for a Quarter Horse. ... racing, among other activities. When loping around a corner in late 2017, Atlas tripped ... horse to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the opinion ...
(Date:5/4/2019)... (PRWEB) , ... May 03, 2019 , ... ... the release of the Diopsys® ffERG/Photopic Negative Response vision test, a ... , By 2050, it is estimated that 6.3 million Americans will have glaucoma, ...
(Date:5/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading ... free, so be sure to register today to save your place! Participate in the ... our upcoming webinars: , CLINICAL TRIALS , May 7 – Oncology Clinical Trials – ...
Breaking Biology Technology: